Gut microbial biomarkers for predicting adverse outcomes in people with chronic kidney disease

Tess E. Cooper, Eric H. Au, Edmund Y.M. Chung, David J. Tunnicliffe, Jonathan C. Craig, Loreto Gesualdo, Martin Howell, Peter Mannon, Roslyn Mannon, Giovanni F.M. Strippoli, Armando Teixeira-Pinto, Allison Tong, Germaine Wong

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: This is a protocol for a Cochrane Review (prognosis). The objectives are as follows:. To (a) identify the gut microbial biomarkers in patients with CKD, on dialysis, and with kidney transplants; (b) determine whether these biomarkers are associated independently with adverse patient-relevant outcomes leading to progression of CKD stages 1 to 5; and (c) explore sources of heterogeneity. Investigation of sources of heterogeneity between studies We will explore potential sources of heterogeneity that may impact outcomes such as differences in study participation; stage of CKD (KDIGO 2013; Appendix 1); study design (cohort, case series, case study), timing of outcome measurements; units and instruments of outcome measurements; and length of follow-up.

Original languageEnglish (US)
Article numberCD014786
JournalCochrane Database of Systematic Reviews
Volume2022
Issue number1
DOIs
StatePublished - Jan 12 2022

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Gut microbial biomarkers for predicting adverse outcomes in people with chronic kidney disease'. Together they form a unique fingerprint.

Cite this